Scoop has an Ethical Paywall
Work smarter with a Pro licence Learn More

Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

Clinical Trial Progress at Annual General Meeting

Living Cell Technologies Updates Shareholders on Clinical Trial Progress at Annual General Meeting

November 27, 2007 – Melbourne, Australia and Auckland, New Zealand Living Cell Technologies Limited (ASX:LCT; OTC: LVCLY.PK) today updated shareholders at its Annual General Meeting on the Company’s Russian clinical trial, the status of its New Zealand clinical trial and commercialisation plans.

Professor Bob Elliot, Medical Director of LCT, announced that a third patient in the Russian Clinical Trial was implanted with the first dose of DiabeCell® and is due for a second dose in six months. DiabeCell® is administered to patients without the need for immunosuppressant drugs.

The first patient implanted with DiabeCell® in June 2007 has maintained a 40% reduction in his insulin requirement at five months followup. This patient is due for a second dose of DiabeCell® in December.

The second patient having received only the first dose of DiabeCell® in September 2007 remains insulin independent at two months follow up.

Professor Elliott stated, ‘ We are very encouraged by the positive preliminary data from the first two patients in the Russian trial and look forward to providing more detailed updates on all three patients by the end of first quarter 2008.'

Dr Paul Tan, CEO of Living Cell Technologies said, ‘ LCT’s most important milestone for 2008 is to complete the Phase I/IIa clinical trial in Russia. Additionally we look forward to receiving endorsement of our ethics and regulatory approval by the new Health Minister which will enable the New Zealand clinical trial to commence.’

Advertisement - scroll to continue reading

Are you getting our free newsletter?

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.

The Company emphasised that while the results to date are preliminary and need to be seen in the context of full clinical trial data, a continuation of the better than expected clinical response is a positive step in the Company’s path towards commercialisation. Accordingly other major milestones over the next 12 months include upscaling the production capabilities and expansion of LCT’s unique pig herd.

ENDS

© Scoop Media

Advertisement - scroll to continue reading
 
 
 
Business Headlines | Sci-Tech Headlines

 
GenPro: General Practices Begin Issuing Clause 14 Notices

GenPro has been copied into a rising number of Clause 14 notices issued since the NZNO lodged its Primary Practice Pay Equity Claim against General Practice employers in December 2023.More

SPADA: Screen Industry Unites For Streaming Platform Regulation & Intellectual Property Protections

In an unprecedented international collaboration, representatives of screen producing organisations from around the world have released a joint statement.More

 
 
 
 
 
 
 
 
 
 
 
 

Join Our Free Newsletter

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.